Limits...
The prognostic significance of protein tyrosine phosphatase 4A2 in breast cancer.

Zhao D, Guo L, Neves H, Yuen HF, Zhang SD, McCrudden CM, Wen Q, Zhang J, Zeng Q, Kwok HF, Lin Y - Onco Targets Ther (2015)

Bottom Line: Although PTP4A3 has been shown to be a very important factor in promoting cancer progression, the role of its close family member PTP4A2 is still largely unknown.Low PTP4A2 expression was associated with estrogen receptor-negative tumors and tumors with higher histological grading; furthermore, low expression was inversely correlated with the expression of genes involved in proliferation, including MKI67 and the MCM gene family encoding the minichromosome maintenance proteins.PTP4A2 expression was positively correlated with ESR1, the gene encoding estrogen receptor-alpha, and inversely correlated with EGFR expression, suggesting that PTP4A2 may be involved in these two important oncogenic pathways.

View Article: PubMed Central - PubMed

Affiliation: College of Continuing Education, Nanjing University of Aeronautics and Astronautics, Nanjing, Jiangsu, People's Republic of China.

ABSTRACT
Although PTP4A3 has been shown to be a very important factor in promoting cancer progression, the role of its close family member PTP4A2 is still largely unknown. Recent reports have shown contradicting results on the role of PTP4A2 in breast cancer progression. Considering this, we aimed to investigate the prognostic value of PTP4A2 in five independent breast cancer data sets (minimum 198 patients per cohort, totaling 1,124 patients) in the Gene Expression Omnibus Database. We found that high expression of PTP4A2 was a favorable prognostic marker in all five independent breast cancer data sets, as well as in the combined cohort, with a hazard ratio of 0.68 (95% confidence interval =0.56-0.83; P<0.001). Low PTP4A2 expression was associated with estrogen receptor-negative tumors and tumors with higher histological grading; furthermore, low expression was inversely correlated with the expression of genes involved in proliferation, including MKI67 and the MCM gene family encoding the minichromosome maintenance proteins. These findings suggest that PTP4A2 may play a role in breast cancer progression by dysregulating cell proliferation. PTP4A2 expression was positively correlated with ESR1, the gene encoding estrogen receptor-alpha, and inversely correlated with EGFR expression, suggesting that PTP4A2 may be involved in these two important oncogenic pathways. Together, our results suggest that expression of PTP4A2 is a favorable prognostic marker in breast cancer.

No MeSH data available.


Related in: MedlinePlus

The correlations between PTP4A2 expression and MKI67 expression.Notes: Scatter plots for PTP4A2 expression against MKI67 expression in (A) GSE2034, (B) GSE3494, (C) GSE7390, (D) GSE11121, and (E) GSE12276 breast cancer data sets.Abbreviations:MKI67, marker of proliferation Ki-67; PTP4A2, protein tyrosine phosphatase 4A2.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4508076&req=5

f4-ott-8-1707: The correlations between PTP4A2 expression and MKI67 expression.Notes: Scatter plots for PTP4A2 expression against MKI67 expression in (A) GSE2034, (B) GSE3494, (C) GSE7390, (D) GSE11121, and (E) GSE12276 breast cancer data sets.Abbreviations:MKI67, marker of proliferation Ki-67; PTP4A2, protein tyrosine phosphatase 4A2.

Mentions: Next, to further elucidate the role of PTP4A2 in breast cancer progression, we investigated whether PTP4A2 expression is correlated with the expression of proliferation-related genes. It has been previously shown that MKI67 is an important prognostic and predictive biomarker in breast cancer.23 In the present study, we investigated the correlation between the expression levels of PTP4A2 and MKI67. As shown in Figure 4, the expression level of PTP4A2 was inversely correlated with the expression level of MKI67 in breast cancer specimens in GSE2034 (r=−0.354, P<0.001; Figure 4A), GSE3494 (r=−0.208, P=0.001; Figure 4B), GSE7390 (r=−0.434, P<0.001; Figure 4C), GSE11121 (r=−0.321, P<0.001; Figure 4D), and GSE12276 (r=−0.271, P<0.001; Figure 4E) breast cancer data sets.


The prognostic significance of protein tyrosine phosphatase 4A2 in breast cancer.

Zhao D, Guo L, Neves H, Yuen HF, Zhang SD, McCrudden CM, Wen Q, Zhang J, Zeng Q, Kwok HF, Lin Y - Onco Targets Ther (2015)

The correlations between PTP4A2 expression and MKI67 expression.Notes: Scatter plots for PTP4A2 expression against MKI67 expression in (A) GSE2034, (B) GSE3494, (C) GSE7390, (D) GSE11121, and (E) GSE12276 breast cancer data sets.Abbreviations:MKI67, marker of proliferation Ki-67; PTP4A2, protein tyrosine phosphatase 4A2.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4508076&req=5

f4-ott-8-1707: The correlations between PTP4A2 expression and MKI67 expression.Notes: Scatter plots for PTP4A2 expression against MKI67 expression in (A) GSE2034, (B) GSE3494, (C) GSE7390, (D) GSE11121, and (E) GSE12276 breast cancer data sets.Abbreviations:MKI67, marker of proliferation Ki-67; PTP4A2, protein tyrosine phosphatase 4A2.
Mentions: Next, to further elucidate the role of PTP4A2 in breast cancer progression, we investigated whether PTP4A2 expression is correlated with the expression of proliferation-related genes. It has been previously shown that MKI67 is an important prognostic and predictive biomarker in breast cancer.23 In the present study, we investigated the correlation between the expression levels of PTP4A2 and MKI67. As shown in Figure 4, the expression level of PTP4A2 was inversely correlated with the expression level of MKI67 in breast cancer specimens in GSE2034 (r=−0.354, P<0.001; Figure 4A), GSE3494 (r=−0.208, P=0.001; Figure 4B), GSE7390 (r=−0.434, P<0.001; Figure 4C), GSE11121 (r=−0.321, P<0.001; Figure 4D), and GSE12276 (r=−0.271, P<0.001; Figure 4E) breast cancer data sets.

Bottom Line: Although PTP4A3 has been shown to be a very important factor in promoting cancer progression, the role of its close family member PTP4A2 is still largely unknown.Low PTP4A2 expression was associated with estrogen receptor-negative tumors and tumors with higher histological grading; furthermore, low expression was inversely correlated with the expression of genes involved in proliferation, including MKI67 and the MCM gene family encoding the minichromosome maintenance proteins.PTP4A2 expression was positively correlated with ESR1, the gene encoding estrogen receptor-alpha, and inversely correlated with EGFR expression, suggesting that PTP4A2 may be involved in these two important oncogenic pathways.

View Article: PubMed Central - PubMed

Affiliation: College of Continuing Education, Nanjing University of Aeronautics and Astronautics, Nanjing, Jiangsu, People's Republic of China.

ABSTRACT
Although PTP4A3 has been shown to be a very important factor in promoting cancer progression, the role of its close family member PTP4A2 is still largely unknown. Recent reports have shown contradicting results on the role of PTP4A2 in breast cancer progression. Considering this, we aimed to investigate the prognostic value of PTP4A2 in five independent breast cancer data sets (minimum 198 patients per cohort, totaling 1,124 patients) in the Gene Expression Omnibus Database. We found that high expression of PTP4A2 was a favorable prognostic marker in all five independent breast cancer data sets, as well as in the combined cohort, with a hazard ratio of 0.68 (95% confidence interval =0.56-0.83; P<0.001). Low PTP4A2 expression was associated with estrogen receptor-negative tumors and tumors with higher histological grading; furthermore, low expression was inversely correlated with the expression of genes involved in proliferation, including MKI67 and the MCM gene family encoding the minichromosome maintenance proteins. These findings suggest that PTP4A2 may play a role in breast cancer progression by dysregulating cell proliferation. PTP4A2 expression was positively correlated with ESR1, the gene encoding estrogen receptor-alpha, and inversely correlated with EGFR expression, suggesting that PTP4A2 may be involved in these two important oncogenic pathways. Together, our results suggest that expression of PTP4A2 is a favorable prognostic marker in breast cancer.

No MeSH data available.


Related in: MedlinePlus